Orphan Teb Pars as a private company was established to position the new options of treatment in Iran pharmaceutical field. Our major goal is making health accessible to all as we aim Iranian people to become one of the healthiest individuals. Currently, we want to supply pharmaceutical and medical device products from reputable multinational companies in Iran. Our company has a decentralized policy which leads us to meet the exact needs of our partners separately. So, business model with our clients could be different from a distributor model to an official agent based on what our partners asking us.
| Website | http://www.orphantebpars.com |
| Revenue | $406000 |
| Employees | View employees |
| Industry | Manufacturing General, Manufacturing |
| Competitors | SUN PHARMA, RPG Life Sciences Ltd., Zydus Cadila Healthcare Limited, Dr. Reddy's Laboratories, Novartis, Cipla, Mylan Belgium, Amgen, Merck Group, Boehringer Ingelheim +40 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Orphan Teb Pars employee's phone or email?
Orphan Teb Pars Questions
The Orphan Teb Pars annual revenue was $406000 in 2026.
The NAICS codes for Orphan Teb Pars are [32541, 32, 3254, 325].
The SIC codes for Orphan Teb Pars are [28, 283].
